Comparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy

Basit Öğe Kaydı
dc.contributor.authorNarin, Cueneyt
dc.contributor.authorReyhanoglu, Hasan
dc.contributor.authorTuelek, Baykal
dc.contributor.authorOnoglu, Rasit
dc.contributor.authorEge, Erdal
dc.contributor.authorSariguel, Ali
dc.contributor.authorYeniterzi, Mehmet
dc.date.accessioned2020-03-26T17:26:32Z
dc.date.available2020-03-26T17:26:32Z
dc.date.issued2008
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractIntroduction: Pregnant women have a higher risk of developing deep vein thrombosis (DVT) and consequent thrombogenic events, including pulmonary embolisms. Low-molecular-weight heparin (LMWH) products have been shown to successfully treat DVT with few significant side effects. The purpose of this study was to compare the effects of two dose regimens of enoxaparin (a LMWH) in the management of DVT in pregnancy. Methods: A total of 35 pregnant patients with DVT were enrolled in this study. As first-line anticoagulation therapy, patients were administered an intravenous unfractionated heparin infusion for 5 days, followed by a subcutaneous injection of enoxaparin 1 mg/kg twice a day until discharge. The enoxaparin therapy continued at home with 1 mg/kg twice a day for 18 patients (group I) and 1.5 mg/kg once a day for the other 17 patients (group II). Enoxaparin was discontinued 12-24 hours before delivery and restarted within 8-12 hours after delivery. Warfarin was given as adjuvant therapy along with enoxaparin in the post-partum period. Enoxaparin was discontinued when an international normalised ratio of 2 or above was reached. Differences between the two groups in terms of therapy response, complications and efficacy were recorded. Results: Thrombophilic disease was observed in three patients in each group. The iliac vein had the highest incidence of DVT in both groups. During therapy, two patients in group I were diagnosed with a mild haemorrhage; one patient (in group II) had abortion. There were no significant differences between groups in terms of recanalisation (measured by venous ultrasonography examination), post-thrombotic symptoms or safety parameters. Results: Enoxaparin can be used safely in DVT therapy during pregnancy. Our results indicate that therapy consisting of a single daily dose of 1.5 mg/kg enoxaparin is as effective as twice-daily administration.en_US
dc.identifier.doi10.1007/s12325-008-0068-0en_US
dc.identifier.endpage594en_US
dc.identifier.issn0741-238Xen_US
dc.identifier.issue6en_US
dc.identifier.pmid18568442en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage585en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s12325-008-0068-0
dc.identifier.urihttps://hdl.handle.net/20.500.12395/22268
dc.identifier.volume25en_US
dc.identifier.wosWOS:000257390500004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSPRINGERen_US
dc.relation.ispartofADVANCES IN THERAPYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjecthaematologicalen_US
dc.subjectlow-molecular-weight heparinen_US
dc.subjectpregnancyen_US
dc.subjectpregnancy complicationsen_US
dc.subjectvenous thrombosisen_US
dc.titleComparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu